Topline results from the Phase III TULIP study show an antibody-drug conjugate (ADC) from the Netherlands-based Byondis B.V. significantly prolonged progression-free survival (PFS) in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer (MBC).

Agreement combines BioAtla’s Conditionally Active Biologic (CAB) antibodies with Pfizer’s Proprietary ADC Payloads Pfizer gains rights to BioAtla CAB immune checkpoint inhibitors targeting CTLA-4   SAN DIEGO, Dec. 7, 2015 /PRNewswire/ — BioAtla LLC, a biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a […]